Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

25.0%

2 terminated/withdrawn out of 8 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

25%

1 of 4 completed trials have results

Key Signals

2 recruiting1 with results

Enrollment Performance

Analytics

Phase 1

4(57.1%)

N/A

2(28.6%)

Early Phase 1

1(14.3%)

7Total

Phase 1(4)

N/A(2)

Early Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT01778686Not ApplicableCompleted

Evaluation of [11C]Cimbi-36 as an Agonist PET Radioligand for Imaging of 5-HT2A Receptors

Role: lead

NCT03289949Phase 1Recruiting

The Neurobiological Effect of 5-HT2AR Modulation

Role: lead

NCT05450822Recruiting

Precision Medicine in the Treatment of Epilepsy

Role: lead

NCT03576664Early Phase 1Completed

Effects of Sleep Deprivation and Adrenergic Inhibition on Glymphatic Flow in Humans

Role: lead

NCT04280055Phase 1Terminated

Prophylactic Effects of Psilocybin on Chronic Cluster Headache

Role: lead

NCT02932488Phase 1Terminated

Cerebral Pharmacodynamic Effects of 5-HT1B Receptor Stimulation

Role: lead

NCT02629003Phase 1Completed

[11C]Cimbi-36 Dosimetry

Role: lead

NCT02661789Not ApplicableCompleted

Neuropsychobiological Correlates of Sex-steroid Hormone Manipulation in Healthy Women: a Risk Model for Depression

Role: lead

All 8 trials loaded